Skip to main content
Sansure Biotech Inc. logo

Sansure Biotech Inc. — Investor Relations & Filings

Ticker · 688289 ISIN · CNE1000043J1 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 870 across all filing types
Latest filing 2025-02-21 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 688289

About Sansure Biotech Inc.

https://www.sansureglobal.com/

Sansure Biotech Inc. specializes in the development and manufacture of molecular diagnostic products and genetic testing solutions. The company utilizes proprietary technologies, such as the "One-tube" fast extraction method and advanced magnetic bead technology, to provide high-sensitivity PCR diagnostic kits. Its product portfolio covers a wide range of clinical applications, including infectious disease screening for hepatitis, respiratory infections, and sexually transmitted infections, as well as oncology and maternal health. Sansure also provides integrated laboratory automation systems, including nucleic acid extractors and real-time PCR instruments, designed to streamline clinical workflows and improve diagnostic efficiency for healthcare providers and research institutions globally.

Recent filings

Filing Released Lang Actions
圣湘生物科技股份有限公司关于收购股权的阶段性进展公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement by 圣湘生物科技股份有限公司 regarding the progress of an equity acquisition transaction. It details the completion of registration changes for the acquired company and payment of part of the purchase price. The document is short (1156 characters) and focuses on providing an update on a financing-related transaction rather than presenting financial statements or detailed financial analysis. It does not contain financial results or management discussion. Therefore, it fits best under Capital/Financing Update (CAP) as it relates to company fundraising and capital structure changes through acquisition.
2025-02-21 Chinese
湖南启元律师事务所关于圣湘生物科技股份有限公司实际控制人增持公司股份的法律意见书
Regulatory Filings
2025-01-27 Chinese
圣湘生物科技股份有限公司关于实际控制人兼董事长及其一致行动人增持股份结果的公告
Major Shareholding Notification Classification · 100% confidence The document is an announcement regarding the completion of a share increase by the company's actual controller and chairman and their concerted parties. It details the shareholding changes, amounts, and compliance with regulatory requirements. The content focuses on the results of a shareholding increase plan, including specific share quantities and percentages. This fits the definition of a Major Shareholding Notification (MRQ), which covers notifications of changes in significant share ownership levels. The document is not a full financial report, earnings release, or management report, nor is it a regulatory filing or announcement of a report publication. Therefore, the appropriate classification is MRQ.
2025-01-27 Chinese
圣湘生物科技股份有限公司关于自愿披露相关产品取得医疗器械注册证的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the voluntary disclosure of obtaining a medical device registration certificate for a product. It includes details about the product, its registration, impact on the company, and risk warnings. The document is short (1334 characters) and does not contain financial statements, earnings data, or detailed financial analysis. It is an official announcement about a regulatory approval related to a product, not a financial report or management discussion. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2025-01-27 Chinese
圣湘生物科技股份有限公司关于收购股权的补充公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding the acquisition of 100% equity of a company (中山海济) by 圣湘生物科技股份有限公司. It discusses the valuation, pricing, valuation adjustment mechanisms, risk factors, and strategic rationale behind the acquisition. The content includes financial projections, valuation multiples, and detailed explanations of the transaction terms and risks. This is a corporate announcement about a capital transaction involving acquisition of equity, not a full financial report, earnings release, or regulatory certification. It is not a merger proxy statement or tender offer form but rather a supplemental announcement about the acquisition terms and valuation adjustments. Therefore, the document fits best under the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes such as acquisitions.
2025-01-24 Chinese
圣湘生物科技股份有限公司2025年第一次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a detailed announcement of the resolutions passed at the 2025 first extraordinary general meeting of shareholders of 圣湘生物科技股份有限公司. It includes information about the meeting date, attendance, voting results on specific proposals, and legal witness statements confirming the validity of the meeting and resolutions. There is no financial data or report content, but rather the official voting results and meeting procedural details. This matches the definition of a Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is 2206 characters, which is consistent with a detailed voting results announcement rather than a full report or presentation.
2025-01-20 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.